Shuqin Li1, Yan Xie2, Wei Zhang3, Junfeng Gao4, Man Wang1, Guoxuan Zheng1, Xing Yin1, Hongping Xia5, Xiang Tao6. 1. Department of Obstetrics and Gynecology, Yijishan Hospital, Wannan Medical College, Wuhu, China. 2. Department of Obstetrics and Gynecology, Yangpu District Central Hospital, Shanghai, China. 3. Department of Pathology, Yijishan Hospital, Wannan Medical College, Wuhu, China. 4. Department of Oncology, Hefei First People's Hospital, Hefei, China. 5. Department of Surgery, Yijishan Hospital, Wannan Medical College, Wuhu, China. Electronic address: xiahp82@gmail.com. 6. Department of Pathology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China. Electronic address: tutufoliage@hotmail.com.
Abstract
BACKGROUND: Interferon alpha-inducible protein 27 (IFI27) is an interferon alpha-inducible protein, which was found to be upregulated in some cancers, such as breast cancer, squamous cell carcinoma, hepatocellular carcinoma, and serous ovarian carcinoma. However, the role of IFI27 in ovarian cancer remains to be elucidated. This study was designed to investigate the role of IFI27 in ovarian cancer tumorigenicity. MATERIALS AND METHODS: The expression of IFI27 was examined in ovarian cancer tissues and cell lines by real time quantitative reverse transcription polymerase chain reaction and immunohistochemistry. The cell migration and invasion was investigated by wound healing and transwell invasion assay. The epithelial-mesenchymal transition markers were detected by Western blotting and the stemness was evaluated by sphere formation. The tumor growth was examined in the athymic mice model. RESULTS: We found that IFI27 is overexpressed in ovarian cancer and associated with patients' survival. Interestingly, we further observed that the expression of IFI27 was associated with the expression of mesenchymal marker vimentin in ovarian cancer. Overexpression of IFI27 induces epithelial-mesenchymal transition and promotes epithelial ovarian cancer cells migration and invasion, tumorigenicity, stemness, and drug resistance. Moreover, overexpression of IFI27 is associated with loss of miR-502 in ovarian cancer. Reexpression of miR-502 inhibits IFI27-induced tumorigenicity, migration, and drug resistance. CONCLUSIONS: These data suggested that IFI27 may be a potential target for developing novel diagnosis strategies and therapeutic interventions.
BACKGROUND:Interferon alpha-inducible protein 27 (IFI27) is an interferon alpha-inducible protein, which was found to be upregulated in some cancers, such as breast cancer, squamous cell carcinoma, hepatocellular carcinoma, and serous ovarian carcinoma. However, the role of IFI27 in ovarian cancer remains to be elucidated. This study was designed to investigate the role of IFI27 in ovarian cancer tumorigenicity. MATERIALS AND METHODS: The expression of IFI27 was examined in ovarian cancer tissues and cell lines by real time quantitative reverse transcription polymerase chain reaction and immunohistochemistry. The cell migration and invasion was investigated by wound healing and transwell invasion assay. The epithelial-mesenchymal transition markers were detected by Western blotting and the stemness was evaluated by sphere formation. The tumor growth was examined in the athymic mice model. RESULTS: We found that IFI27 is overexpressed in ovarian cancer and associated with patients' survival. Interestingly, we further observed that the expression of IFI27 was associated with the expression of mesenchymal marker vimentin in ovarian cancer. Overexpression of IFI27 induces epithelial-mesenchymal transition and promotes epithelial ovarian cancer cells migration and invasion, tumorigenicity, stemness, and drug resistance. Moreover, overexpression of IFI27 is associated with loss of miR-502 in ovarian cancer. Reexpression of miR-502 inhibits IFI27-induced tumorigenicity, migration, and drug resistance. CONCLUSIONS: These data suggested that IFI27 may be a potential target for developing novel diagnosis strategies and therapeutic interventions.
Authors: Eric A Ariazi; John C Taylor; Michael A Black; Emmanuelle Nicolas; Michael J Slifker; Diana J Azzam; Jeff Boyd Journal: Mol Cancer Res Date: 2016-11-15 Impact factor: 5.852
Authors: Jeffrey J Quinn; Matthew G Jones; Ross A Okimoto; Shigeki Nanjo; Michelle M Chan; Nir Yosef; Trever G Bivona; Jonathan S Weissman Journal: Science Date: 2021-01-21 Impact factor: 47.728
Authors: J K Dunnick; D L Morgan; S A Elmore; K Gerrish; A Pandiri; T V Ton; K R Shockley; B A Merrick Journal: Toxicol Lett Date: 2016-11-30 Impact factor: 4.372
Authors: Tatjana Sauerer; Christopher Lischer; Adrian Weich; Carola Berking; Julio Vera; Jan Dörrie Journal: Front Microbiol Date: 2021-12-22 Impact factor: 5.640